氯雷他定逐量递减联合孟鲁司特治疗慢性荨麻疹的疗效观察

By The Observation of Decreasing Amount of Loratadine and Montelukast in Treatment of Chronic Urticaria

目的观察氯雷他定逐量递减联合孟鲁司特治疗慢性荨麻疹的疗效。方法采用随机平行对照的临床试验,两组各60例,治疗组予口服氯雷他定按病情逐量递减并联合孟鲁司特,对照组仅于发作时予氯雷他定治疗,追踪观察1年,比较两组患者临床症状缓解及病情反复情况。结果治疗组与对照组比较,4个月后复发率明显下降,有显著差异(P<0.01)。治疗后未见不良反应事件发生。结论氯雷他定逐量递减联合孟鲁司特治疗能有效、长期预防慢性荨麻疹的复发,且安全性好。

Objective To observe the effect of loratadin gradually declinedd, combined with montelukast in treatment of urticaria chronica. Method One hundred and twenty patients with urticaria chronica were randomly divided into two groups, the treatment group received loratadin gradually decline, combined with montelukast. The control group attack treatment with loratadin, follow-up visits 12 months to compared two groups clinical symptom remission and relapse. Results Compared to that of the control group, there was a significant decrease of recurrence rate in the treatment group （P〈0.01）. No drug-related serious side-effects were associated with its long- term use. Conclusion Loratadin gradually declined, combined with montelukast is a new and safe and remarkably effective approach to the prevention of the recurrence of urticaria chronica.